EP300 and neoplasm: Given that HDAC inhibitors (HDACi) induce surface expression of NKG2D-ligands on tumor cells in a CBP/p300-dependent manner [17] we hypothesize that SKI suppresses NKG2D-ligands on pancreatic cancer cells supporting immune evasion.